{"id":"NCT00267150","sponsor":"Novartis Pharmaceuticals","briefTitle":"Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants","officialTitle":"Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2005-12-20","resultsPosted":"2010-12-24","lastUpdate":"2011-05-20"},"enrollment":31,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pancreas Transplantation","Kidney Transplantation"],"interventions":[{"type":"DRUG","name":"Enteric-coated mycophenolate sodium (EC-MPS)","otherNames":["myfortic"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients. This study will assess if a switch from MMF to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI and/or health-related quality of life outcomes and determine the proportion of pancreas-kidney transplant recipients who experience any GI complaints under MMF-based immunosuppressive treatment.","primaryOutcome":{"measure":"Changes in Gastrointestinal Symptom Severity and/or Health-related Quality of Life After Conversion From MMF to Enteric Coated Mycophenolate Sodium","timeFrame":"weeks 6-8","effectByArm":[{"arm":"Enteric Coated Mycophenolate-sodium","deltaMin":-0.46,"sd":0.71}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["Constipation"]}}